Pacific Biosciences Of California (PACB) Cash & Equivalents Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | Pacific Biosciences Of California | 481.66 Mn | 205.70 Mn | 12.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -42.97% |
| Dec 31, 2025 | -4.83% |
| Sep 30, 2025 | -3.94% |
| Jun 30, 2025 | 4.80% |
| Mar 31, 2025 | -3.21% |
| Dec 31, 2024 | 13.32% |
| Sep 30, 2024 | 18.71% |
| Jun 30, 2024 | 26.80% |
| Mar 31, 2024 | 14.94% |
| Dec 31, 2023 | 57.03% |
| Sep 30, 2023 | 58.91% |
| Jun 30, 2023 | 55.45% |
| Mar 31, 2023 | 69.28% |
| Dec 31, 2022 | 81.50% |
| Sep 30, 2022 | 63.66% |
| Jun 30, 2022 | 53.46% |
| Mar 31, 2022 | 71.39% |
| Dec 31, 2021 | 94.00% |
| Jun 30, 2021 | 79.35% |
| Mar 31, 2021 | 115.46% |
| Dec 31, 2020 | 19.40% |
| Sep 30, 2020 | 20.47% |
| Jun 30, 2020 | 10.82% |
| Mar 31, 2020 | 17.87% |
| Dec 31, 2019 | -4.06% |
| Sep 30, 2019 | -1.35% |
| Jun 30, 2019 | 1.49% |
| Mar 31, 2019 | -1.53% |
| Dec 31, 2018 | -6.49% |
| Sep 30, 2018 | -10.09% |
| Jun 30, 2018 | -10.80% |
| Mar 31, 2018 | -13.65% |
| Dec 31, 2017 | -18.72% |
| Sep 30, 2017 | -4.45% |
| Jun 30, 2017 | 1.64% |
| Mar 31, 2017 | -12.42% |
| Dec 31, 2016 | -22.21% |
| Sep 30, 2016 | -16.92% |
| Jun 30, 2016 | -14.59% |
| Mar 31, 2016 | -25.00% |
| Dec 31, 2015 | -25.61% |
| Sep 30, 2015 | -15.38% |
| Jun 30, 2015 | -22.06% |